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ABSTRACT
ROLE OF C-KIT IN THE GROWTH, MIGRATION AND DIFFERENTIATION OF
HUMAN CARDIAC PROGENITOR CELLS
Bathri N. Vajravelu
April 14, 2015

The belief that adult mammalian heart lacks regenerative potential was challenged by
the identification of c-kit positive cardiac progenitor cells (CPCs) in the heart. A
recent phase I clinical trial (SCIPIO), has shown that autologous c-kit positive CPCs
improve cardiac function and quality of life when transplanted into ischemic heart
disease patients. c-Kit is a type III receptor tyrosine kinase and a common stem cell
antigen. Stem cell factor (SCF) is the only known ligand for c-kit. Although c-kit is
extensively used as an invariable marker of resident CPCs and shown to be important
in the context of different cell types, there is no information on its role in the
regulation of cellular characteristics of CPCs. This led us to hypothesize that c-kit
plays a role in the regulation of survival, growth and migration of human CPCs. To
test this hypothesis, CPCs were grown under stress conditions (e.g., serum starvation
and oxidative stress) in the presence or absence of SCF. The effects of SCF-mediated
activation of c-kit on CPC survival/growth were measured using cell viability assay,
BrdU labeling and caspase 3/7 activity assay. I observed a statistically significant
increase in cell survival with SCF treatment compared to the untreated control when
CPCs were subjected to serum depletion. However, SCF treatment did not lead to a
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significant increase in cell viability against 2,3-dimethoxy-1,4-naphthoquinone
(DMNQ) or hydrogen peroxide (H2O2) induced oxidative stress. Furthermore, the prosurvival effect of SCF was augmented by c-kit overexpression and abrogated by cotreatment with imatinib, an inhibitor of c-kit, suggesting that necessity of c-kit activity
for the effect of SCF. I then checked if activation of c-kit can promote migration of
CPCs. I found that CPCs were highly chemotactic to SCF showing a statistically
significant increase in cell migration after SCF treatment. The results of the
differentiation study are not convincing and need further experiments to derive a
conclusion. We also found that SCF treatment on CPCs activated the
phosphoinositide 3-kinase (PI3K) and the mitogen activated protein kinase (MAPK)
pathways. With the use of specific inhibitors, we confirmed that the SCF dependent
survival and chemotaxis of CPCs are dependent on these two pathways. In
conclusion, the results of our experiments suggest that c-kit promotes the survival,
growth and migration of CPCs cultured ex vivo via the activation of PI3K and MAPK
pathways. These results imply that the efficiency of homing of CPCs to the injury site
as well as their post-transplantation survival may be improved by modulating the
activity of c-kit.
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CHAPTER I
GENERAL INTRODUCTION

The report presented in this dissertation is a summary of my research on the
role of c-kit in the growth, survival, migration and differentiation of human cardiac
progenitor cells (CPCs). For a novice reader, it is essential to have an understanding
about the cardiac progenitor cells, c-kit, the scientific evidences that guided the design
of my study and the rationale behind our hypotheses. For this purpose, the first
chapter is dedicated to educate the reader on the available information about CPCs, ckit and its most common biological functions that are relevant to the hypotheses of
this project. I believe the results of this study will bring in new ideas and further
research in establishing the critical role of c-kit and CPCs in cardiac regenerative
therapy.

c-Kit Positive Cardiac Progenitor Cells:
Mammalian heart was considered as a terminally differentiated organ for a
long time until the beginning of this century when several studies challenged the
notion by reporting the renewal of cardiomyocytes [1-3]. These studies established the
fact that adult mammalian heart has the inherent capacity to regenerate although to a
limited extent. The interesting discovery about the regenerative potential of the heart
initiated a number of studies that investigated the presence of resident
stem/progenitor cells in the heart that contribute to tissue maintenance and repair [46].The results of these studies indicated that heart has a reserve of its own primitive
1

cell population that could contribute to the regeneration process upon injury. These
stem cell populations were identified based on their expression of common stem cell
antigens, such as c-kit [4, 7, 8] and Sca-1[9-11] or on their ability to efflux a
fluorescent dye, Hoechst 33342 (“side population”) [12-14] or to form spherical
bodies (“cardiospheres”) under a specific culture condition [15-17] or by the presence
of a progenitor transcription factor islet-1(Isl1+ CPCs) [18, 19]. Among the above list
of primitive cell populations, the c-kit positive CPCs were chosen as a subject for this
study because of its proven efficacy in myocardial regeneration in animals [4, 20] and
in humans [6].
A report by Beltrami et al. in 2003 was the first to demonstrate that heart
harbors a group of cells with properties of cardiac progenitor cells (CPCs) identified
by their expression of the stem cell marker, c-kit [4]. When these c-kit+ cells were
isolated and grown in culture, they were self-renewing, clonogenic, and multipotent,
being able to differentiate into cardiomyocytes, smooth muscle and endothelial cells
both in vitro and in vivo confirming their stemness. Upon isolation and analysis, they
were found to be negative for the panleukocyte marker CD45 and hematopoietic
marker CD34 indicating they did not originate from the bone marrow [4]. These cells
expressed Ki67, a cell cycle marker indicating that these are proliferating cells and
they also expressed certain cardiac transcription factors like GATA4, NKX2.5, MEF2
suggesting their cardiomyogenic commitment. However, these were found to be
negative for mature myocyte, endothelial, smooth muscle cell and fibroblast lineage
markers and thus were characterized as lineage negative (Lin-).
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Cardiac Progenitor Cell Niches:
CPCs are found to be situated in specialized niches in the myocardium mostly
in the apex and atrium of the heart and are less abundant at the base and in the
ventricle [21]. They are connected to the surrounding cardiac cells through gap and
adherens junctions [22]. These junctions facilitate communication between the cells
and also anchor the CPCs to the surrounding microenvironment [23]. Sanada et al
recently reported that based on the oxygen tension, the niches can be either hypoxic or
normoxic [24]. While the normoxic niches contain actively dividing functional CPCs,
the hypoxic niches are a storehouse of quiescent, non-dividing CPCs. The study found
that the number of hypoxic non-dividing CPCs increase with aging, indicating that the
aged heart has a greater accumulation of non-functional CPCs that do not participate
in tissue repair. Interestingly, c-kit activation was found to reverse this balance and
enrich the senescent heart with younger, actively dividing CPCs. When the authors
injected SCF in the heart of aged mice they found a significant increase in the number
of functional CPCs with a concomitant reduction in the number of quiescent CPCs.
This indicates that SCF induced c-kit activation repopulated the senescent heart with
functional CPCs similar to younger hearts. The study also established that these newly
activated CPCs are derived from the quiescent CPC pool further supporting the
importance of c-kit activation in maintaining functional CPC niches in the heart and
its contribution to myocardial rejuvenation.

Therapeutic Potential of Cardiac Progenitor Cells:
Functionally, injecting these cells (marked by EGFP expression) in the border
zone of infarcted hearts in rats significantly regenerated the myocardium when
compared to the control animals. The regenerated myocardium was found to have
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significant number of myocytes that were expressing EGFP confirming their origin
from the injected cells [4]. Similarly, another study found that intracoronary injection
of these cells in a rat model can reduce left ventricular remodeling after MI and also
the infarct size by 29% compared to the control rats [25] adding more support to the
role of these cells in cardiac regeneration. Although the mechanism by which these
cells contribute to the regeneration process is still under investigation, co-culturing
these CPCs with mature cardiomyocytes was found to induce their own differentiation
to cardiomyocyte and also promoted the survival of the co-cultured cardiomyocytes
[26] substantiating that these cells are essential for cardiomyocyte survival and
regeneration. In summary, all the above findings strongly suggest that the c-kit
positive cardiac progenitor cells have the capacity to differentiate in to cardiac cells
and can regenerate the infarcted myocardium.
Supported by the encouraging role of c-kit+ CPCs in cardiac regeneration in
animal models, the therapeutic transplantation of these cells were tested in a phase I
clinical

trial

“SCIPIO”

(Stem

Cell

Infusion

in

Patients

with

Ischemic

CardiOmyopathy) [6]. The study was conducted by the group directed by Dr. Roberto
Bolli, Division of Cardiovascular Medicine in the University of Louisville, KY on
patients suffering from ischemic cardiomyopathy. In this trial, CPCs were isolated
from the atrial appendages of patients with heart failure secondary to myocardial
infarction when they were undergoing coronary artery bypass grafting (CABG). The
isolated cells were expanded and autologous transplantation of CPCs was performed
via an intracoronary injection. The initial results of this clinical trial confirmed that
autologous transplantation of c-kit+ CPCs can significantly improve the heart
function and the quality of life in patients suffering from ischemic cardiomyopathy.
The left ventricular ejection fraction (LVEF) which is a marker of LV function
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improved by nearly 8% within 4 months after injecting these cells whereas there was
no change in the LVEF in the untreated control patients . In the same period, the mean
infarct size reduced by 24% after injecting these CPCs in the patients [6]. A more
important finding of the study is that the regenerative effects of CPC transplantation
were sustained in a majority of the treated patients a year after transplantation. The
study reported that at the end of one year after CPC transplantation, the infarct size in
the treated patients reduced significantly to about 30% lesser than the baseline,
confirmed by an MRI. The results of this study clearly demonstrate the utility of ckit+ CPCs in cardiac regeneration in human beings.

Recent Controversy on CPCs:
Some of the studies published recently questioned the myogenic potential and
the importance of c-kit+ CPCs in the regeneration of injured myocardium. For
example, Berlo et al [27] used the Cre-lox based lineage tracing technique to analyze
the fate of the c-kit+ cells. The results of this study demonstrated that although c-kit+
progenitors generate significant amount of endothelial cells, they contribute to less
than 1% of the cardiomyocytes in the developing, adult and injured heart, questioning
their functional importance. However the authors failed to address the caveats that are
associated with their experimental design. For instance, the recombination efficiency
in c-kit+ CPCs is largely ignored. Estimating the contribution of the c-kit+ CPCs to
myogenesis is completely dependent on the expression of the reporter gene that will
be turned on after effective recombination. Hence without this data, the results
derived are largely inconclusive. Furthermore, no control was provided to show that
the c-kit expression in the recombined cells is identical to the WT or the unmodified
gene. Also Cre expression has been shown to be toxic to the cells [28] and the authors
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failed to add information about the toxicity of Cre in their system. Without
experimentally addressing these critical issues, the results obtained through this study
by Berlo et al certainly do not support the conclusion that c-kit+ CPCs are not
functionally important. Another study by Cheng et al [29] depleted the c-kit fraction
of the cardiosphere derived cells (CDCs, another heart derived progenitor cell
population) and demonstrated that the functional benefits of CDCs in an animal model
of myocardial infarction is not compromised after depleting the c-kit+ cells, raising
concerns about the relevance of resident c-kit+ CPCs in myocardial regeneration. The
authors demonstrated that attenuation of left ventricular remodeling was greater in
CD90 depleted CDCs and in double depleted (CD90 and c-kit depleted) population
than the unsorted CDCs, while the c-kit depleted CDCs were similar to the unsorted
CDC group. The authors also mentioned that the CDCs contained only a small
fraction of c-kit+ cells (0.3% to 7.2%) and the percentage was highly variable from
patient to patient. On the other hand, the CD90 expression varied broadly from 0.2%
to 94.6% indicating that the CDCs contain a very high proportion of CD90+ cells and
a minor population of c-kit+ cells. The results also showed that functionally, the
unsorted CDCs are similar to the c-kit depleted CDCs and the CD90 depleted fraction
in all cases is similar to the double depleted fraction. This further corroborates that the
c-kit+ cells constitute a minor fraction of CDCs and therefore the results of this study
cannot stand alone to invalidate the role of c-kit+ CPCs in cardioprotection.
In contrast, diametrically opposed results have been reported by other studies
that support the notion that c-kit+ CPCs are indispensable for remuscularization of the
heart [25, 30, 31]. For instance, in an animal model of isoproterenol (ISO) induced
MI, Ellison and colleagues [20] have shown that the endogenous CPCs are crucial and
are sufficient to regenerate the myocardium after injury. The authors found 88% of
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CPCs were BrdU+ at day 3 after MI and were maintained significantly higher up to
28 days when compared to the uninjured control rats. Many of the c-kit+ CPCs
expressed GATA4 and NKX2.5 indicating their commitment to cardiovascular
lineage. They also found that starting at day 3, BrdU+ Ki67+ cardiomyocytes
increased gradually in size and number from day 3 to day 28 suggesting active
myogenesis. Using a tamoxifen inducible GFP expression system the authors
demonstrated that the pre-existing cardiomyocytes and the bone marrow cells do not
contribute to the myogenesis in the injured heart. To confirm the newly formed
cardiomyocytes are from the endogenous CPCs, they used lentivirus to express YFP
in the c-kit expressing cells of the heart and found that a significant proportion of
cardiomyocytes originated from the CPCs identified by their YFP expression.
To further ascertain that the CPCs are sufficient for myocardial regeneration,
the authors eliminated the proliferating CPCs with the anti-mitotic agent 5-Fluouracil
(5-FU). Next, they injected ISO followed by the injection of GFP+ CPCs or GFP+
cardiac fibroblasts in the tail vein. Only the CPCs injected group recovered from ISO
induced cardiac failure at 2 months after injection. To confirm if the recovery was
indeed because of the injected CPCs, the authors induced suicide of the injected cells
that co expressed herpes simplex virus thymidine kinase (HSVTK) along with GFP by
administering ganciclovir. Selective suicide of the transplanted CPCs recapitulated the
cardiac failure phonotype confirming that the regeneration was exclusively due to the
injected c-kit+ CPCs.

Among the injected GFP+ CPCs, around 68% formed

cardiomyocytes while they also observed 13% of smooth muscle cells and 17% of
endothelial cells originating from the injected cells. More interestingly, the
transplanted GFP+ CPCs upon reisolation and testing were found to retain their stem
cell properties. Taken together, these results unequivocally support the conclusion that
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the endogenous c-kit+ CPCs are sufficient and are essential for the structural and
functional regeneration of the infarcted heart.

Survival of CPCs After Transplantation:
Cellular therapy for the regeneration of ischemic myocardium is a promising
option but several studies identified poor survival of the transplanted cells limiting the
treatment outcome. For example, in a study conducted by Hayashi et al, upon
injecting the bone marrow cells in a rat model of acute MI, the investigators found
that only 6% of the delivered cells survived at the end of 3 days [32]. Similarly, in a
porcine model of MI, only 5% of the mesenchymal stem cells that were delivered via
an intracoronary infusion survived at the end of 14 days after transplantation [33].
Substantiating the findings of the above studies, Hong et al have recently shown that
when CPCs were delivered via the intracoronary route after inducing MI in a mouse
model, only 5% of the injected cells survived at the end of day 1 and only 1% of the
injected cells were detected at the end of 35 days in the heart [34]. The findings of the
above studies indicate that regardless of the cell source, it is critical to improve the
survival of the transplanted cells to achieve successful regeneration of the infarcted
myocardium. Better survival of the grafted cells can be accomplished by improving
the homing capacity of the cells or its growth or by reducing the death of the
transplanted cells. For this purpose, to achieve significant remuscularization of the
ischemic myocardium with CPC based therapy, it is imperative to identify key
regulators that can influence the cellular properties of CPCs.
The search guided our laboratory to investigate if the stem cell marker c-kit
can be the key protein regulating the growth, survival, migration and differentiation of
CPCs because of the well-established mitogenic, chemotactic and pro-survival effects

8

of this protein in various cell types. Although c-kit so far has been only used as a
surface antigen for identifying CPCs, it has been recognized to play a critical role in
regulating survival, proliferation, differentiation, migration and engraftment of mast
cells [35], melanocytes [36, 37], germ cells [38, 39] and hematopoietic stem cells
[40]. A description on the role of c-kit in some of the above cell types is discussed
later in this manuscript. In spite of an established role of c-kit in mediating the
survival and migration benefits in a wide variety of cell types, to my knowledge, no
studies so far have explored the role of c-kit in the regulation of cellular
characteristics in CPCs. This directed us to design the study presented here in which I
hypothesized that c-kit plays a role in the survival, growth, migration and
differentiation of CPCs. To test this hypothesis, I measured the effect of SCF
mediated activation of c-kit on the survival, growth, migration and differentiation of
the CPCs and analyzed the mechanism through which these effects are mediated.
Before discussing the experimental results on testing the effect of c-kit
activation on the growth, survival, migration and differentiation of CPCs, it is
essential to know the basic information about the protein c-kit and its ligand, the stem
cell factor or SCF. A short description about the two proteins is given below.

Introduction to c-Kit:
Cellular Kit (c-kit) (also known as CD117 or stem cell factor receptor) was
discovered in the year 1986 as the cellular homolog of the viral oncogene v-kit. It was
identified to be the transforming gene of the Hardy-Zuckerman 4 feline sarcoma virus
and hence named “kit”, an abbreviation for “kitten” [41]. The gene encodes a 145 kDa
transmembrane glycoprotein that belongs to type-III receptor tyrosine kinase (RTK)
family, which includes platelet derived growth factor receptor (PDGFR) and
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macrophage colony stimulating factor 1 receptor (CSF-1) [41-43]. Soon after the
discovery of c-kit, based on the phenotype of c-kit mutants, it was found that it is
allelic with the dominant white spotting locus (W) of mice [44]. Similar phenotype
was also found in the mice with mutation in the Steel (Sl) locus leading to the
discovery of the only known ligand for c-kit called the steel factor or the stem cell
factor (SCF), the product of Sl locus [45, 46].
The c-kit protein has approximately 976 amino acids and the core protein is
around 110 kDa in molecular weight. The protein undergoes N-linked glycosylation
after translation increasing the weight of the mature protein to approximately 145
kDa. Similar to other type III RTKs, the protein has five extracellular
immunoglobulin (Ig) like domains followed by a single transmembrane helix and a
short cytoplasmic transmembrane domain (Figure 1). The intracellular part of the
protein has two kinase domains separated by a short kinase insert and ends in a
carboxy terminus [41]. The c-kit gene was found to be located in the chromosome
4q11 in humans. It has 21 exons covering around 34 kb of DNA [41, 47].

Functional Role of c-Kit:
The idea of testing c-kit in the regulation of the growth, survival, migration
and differentiation of CPCs is supported by extensive evidences that are available on
this well characterized RTK. Besides being used as a stem cell marker, it is a protooncogene and activating mutations in c-kit gene are frequently associated with various
types of tumors, such as mast cell tumors, gastrointestinal stromal tumors (GIST), and
leukemia [48-50]. In addition to its role as an oncogene, this protein is critical to
maintain normal hematopoiesis [40, 51], pigmentation [36, 52], gametogenesis [53,
54], immune response [55, 56], intestinal motility [57, 58], vasculogenesis [59], lung
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compliance [60, 61], brain development [62], etc. Although it is beyond the focus of
this manuscript to explain all the roles played by c-kit in detail, a brief description of
few of them is given below. These reports on the cellular functions of c-kit directed us
to test if the activation of c-kit can influence specific cellular properties and pathways
in CPCs.

Role of c-Kit in Melanocytes:
c-Kit was originally identified when scientists attempted to find the key
molecule that caused white spotting in mice. It was found to be due to a defective
migration in melanocytes caused by a loss of function mutation in c-kit or its ligand
SCF [47, 63]. Since then, the role of c-kit and SCF in the development, survival and
migration of melanocytes has been extensively studied. For example, Luo et al have
shown that SCF dependent activation of c-kit in cultured melanocytes induces the
transcription of tyrosinase gene which is involved in melanogenesis [64]. Studies on
the expression patterns of c-kit among different species have indicated that
melanocytes are dependent on the activation of c-kit receptor for the migration of its
precursors and also for their proliferation and survival [65]. It is interesting to note
that the neural crest cells which are the precursors of melanocytes were found to
express c-kit as early as embryonic day 9.5 in the head. These precursors then migrate
towards the eyes, inner ears and into the second brachial arch [66, 67]. When there is
a mutation in c-kit gene, this migration of melanocyte precursors is blocked and they
undergo apoptosis resulting in depigmented patches. Study on mouse hair follicle
(HF) melanocytes showed that the proliferation of these melanocytes is dependent on
c-kit activation [36, 68, 69]. Immunohistochemical analysis of HF melanocytes for
Ki-67 and c-kit revealed that only the c-kit expressing subset was actively
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proliferating.

SCF overexpression in mice significantly increased this actively

dividing subset of melanocytes and using a c-kit blocking antibody significantly
reduced the number of proliferating HF melanocytes indicating that the mitogenic
effect observed was indeed mediated through the activation of c-kit [36]. Taken
together, these results indicate that c-kit is an indispensable regulator of melanocyte
biology by acting as a mitogen, pro-migratory and pro-survival agent.

Role of c-Kit in Mast Cells:
The role of c-kit in regulating the cellular characteristics of mast cells has been
extensively studied. c-Kit has been reported as the key molecule regulating the
proliferation, survival, migration, differentiation and secretory functions of mast cells.
Mast cells are one of the cell types that maintain c-kit expression after maturation, in
addition to the dendritic cells and natural killer cells. Mice with c-kit mutation (W/Wv)
were found to have profound mast cell deficiency [70] indicating the critical function
of c-kit in mast cell development. Published studies have shown that withdrawing
SCF from the media in which mast cells are grown induce apoptosis within 48 hours,
identified by DNA fragmentation. Replenishing the media with SCF in the same
system could rescue the dying cells demonstrating the anti-apoptotic role of c-kit
activation [71]. The mitogenic role of c-kit activation is well established in the bone
marrow derived mast cells (BMMC) from mice. It was shown that upon activation of
c-kit with SCF, BMMC doubled in number within 48 hours of incubation with the
growth factor and the effect was further enhanced by the inclusion of serum [35]. In
addition, the same group reported that SCF treatment is required for the BMMCs to
enter cell cycle and its availability in the media is critical for the cells to complete the
cell cycle and survive [35]. Interestingly, along with the other growth factor IL-3,
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SCF could promote the differentiation of pro-mastocyte to mast cells [72]. c-Kit
activation was found to promote the migration and mediator release by cutaneous and
lung mast cells [73, 74]. Migration of mast cells along a gradient of SCF has been
shown to be essential in regulating the mast cell biology [74]. In addition to its prosurvival, mitogenic and chemotactic effects, SCF dependent c-kit stimulation in mast
cells was found to cause degranulation and cytokine release. For example, it was
shown that c-kit activation could enhance IgE dependent histamine and leukotriene
C4 release from human lung mast cells [73] and histamine and prostaglandin release
from human cutaneous mast cells [75]. When combined with the results on the role of
c-kit in melanocytes, it is clear that c-kit has similar roles in different cell types,
acting as a pro-survival, pro-growth and a chemotactic agent.

Role of c-Kit in Hematopoietic Cells:
SCF-c-kit axis has an essential role in maintaining normal hematopoiesis.
Hematopoietic cells are found to express c-kit as early as day 8 post-gestation in the
mouse embryonic yolk sac. The expression increases until day 15 post-gestation and
then gradually decreases [76]. Any aberration in the normal expression of c-kit in the
embryonic stage due to a homozygous c-kit mutation is lethal in mice due to severe
anemia [77-79]. Studies have shown that transplanting the bone marrow of c-kit
mutant white spotted (W/Wv mutant) mice could not replenish cellularity in irradiated
hosts confirming that c-kit is essential for normal hematopoiesis [80]. The bone
marrow of these mutants were found to have significantly lesser colony forming units
spleen (CFU-S), colony forming unit erythroid (CFU-E) and colony forming unitgranulocyte-macrophage (CFU-GM) when compared to their control littermates
thereby affecting their capacity to reconstitute the bone marrow cellularity upon
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transplantation into the hosts [81-84]. SCF-c-kit signaling plays a vital role in the
development and function of both hematopoietic stem/progenitor cells as well as
mature cells. For example, it was found that c-kit activation was able to promote the
proliferation and survival of hematopoietic stem cells (HSCs) [85]. In a study by
Leary et al SCF in combination with IL-3 was able to shorten the G0 phase of the
HSCs and drive them to enter the cell cycle, suggesting a mitogenic role for c-kit in
HSCs [86]. Furthermore, activation of the c-kit receptor by SCF treatment in an
enriched population of long term repopulating HSCs has been shown to significantly
increase its survival compared to the cells grown in the medium without SCF [85].
Interestingly, SCF was found to have a synergistic effect with other cytokines like
erythropoietin (Epo), granulocyte colony stimulating factor (G-CSF), granulocyte
macrophage colony stimulating factor (GM-CSF) and could promote the proliferation
as well as the colony size of blood forming unit – erythroid (BFU-E), CFU-GM and
colony forming unit - granulocyte, erythrocyte, monocyte, megakaryocyte (CFUGEMM) [87-89]. Besides playing a crucial role in the maintenance and regeneration
of HSCs, c-kit also plays a role in the interaction of HSCs with the niche cells like the
endothelial cells and the stromal cells in the bone marrow. This interaction is essential
for the motility, survival and proliferation of HSCs, as the bone marrow stromal cells
and endothelial cells are an endogenous source of the kit ligand, SCF [90]. In addition
to its role in steady state conditions, many studies have highlighted the function of ckit in the hematopoietic compartment under conditions of stress like ischemic cardiac
injury. For example, Fazel et al have highlighted that there is an increase in the
myocardial expression of SCF after ischemic cardiac injury which mobilizes and
recruits c-kit+ hematopoietic progenitor cells to the site of injury and contribute to
regeneration. In the same model, deletion of c-kit was found to cause cardiac failure

14

after the ischemic insult which could be rescued by transplantation of wild type bone
marrow [91] indicating the critical role of SCF-c-kit signaling in cardiac regeneration.
In summary, these results strongly suggest that the SCF-c-kit axis is an essential
component of the hematopoietic compartment and is crucial for the growth, survival
and migration of the hematopoietic cells under normal and also in conditions of stress.
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Figure 1: Schematic representation of the structure of c-kit: The type III receptor
tyrosine kinase has five extracellular Ig like domains, followed by a short
transmembrane domain. The intracellular region has two kinase domain separated by
a short kinase insert and ends in a carboxy terminus.
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Steel Factor or the Stem Cell Factor:
Stem cell factor (SCF), also known as steel factor or kit ligand is the only
known ligand for c-kit. The gene encoding SCF is on chromosome 12 in humans and
has 9 exons [92, 93]. The protein exists as a membrane bound isoform and a soluble
isoform (Figure 2). The two isoforms differ in the presence or absence of exon 6
which encodes a proteolytic cleavage site. Both isoforms when produced are attached
to the cellular membrane. The membrane bound isoform has 220 amino acids and the
soluble isoform has 248 amino acids [94]. The soluble isoform has exon 6 containing
the cleavage site and hence gets cleaved by several proteases like matrix
metalloproteases (MMPs), chymase-1 as well as ADAM family proteases to yield a
shorter 165 amino acid containing soluble SCF [95-97]. Both the isoforms are
biologically active; however, there are significant differences in the intensity and
duration of c-kit activation induced by these isoforms [98]. When the cells were
treated with soluble SCF, they were found to induce rapid internalization and
degradation of the c-kit receptor whereas the membrane bound isoform was found to
cause a much prolonged activation of the c-kit receptor and delay the receptor
internalization and degradation [99]. It is well known that certain cells like the
endothelial cells, fibroblasts and bone marrow stromal cells express SCF which is
involved in regulating proliferation, survival, migration and differentiation of its own
or the surrounding c-kit positive cells [46, 94, 100]. The regulation of SCF expression
is found to be very less understood. Studies have shown that conditions like hypoxia
and myocardial infarction can cause an increase in SCF expression [91, 101, 102].
Moreover, exposure to UVB light and follicle stimulating hormone (FSH) treatment
were also found to have a similar effect [103, 104]. It is also regulated by post-
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translational modification as the protein was found to undergo both N-linked and Olinked glycosylation [105].
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Figure 2: Schematic representation of the structure of SCF: The ligand for c-kit,
SCF has two isoforms; the membrane bound and the soluble isoform. Both are
synthesized as a membrane bound form but the longer transcript gets cleaved by
proteases due to the presence of the cleavage site, producing soluble SCF.
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c-Kit Receptor Activation, Downregulation & Inhibition:
Similar to other growth receptors like PDGFR and EGFR, c-kit dimerizes
upon ligand binding causing autophosphorylation of its tyrosine residues resulting in
receptor activation [106]. The extra cellular immunoglobulin (Ig) like domain is
critical for ligand binding and dimerization. The ligand SCF binds to adjacent c-kit
receptors at the first three Ig like domains inducing a conformational change in the Ig
like domains 4 and 5 thereby bringing adjacent c-kit monomers in close proximity.
When the receptor is inactive, the juxtamembrane domain interacts with the kinase
domain and inhibits its enzyme activity [106-108]. However, upon ligand stimulation
and dimerization, specific tyrosine residues (Tyr-568 and Tyr-570) in the
juxtamembrane domain get phosphorylated causing a conformational change
releasing its inhibitory configuration on the kinase domain. Upon resuming the
enzyme activity, the kinase domain phosphorylates other tyrosine residues
(autophosphorylation) resulting in receptor activation [108, 109].
Down regulation of c-kit activity can occur through three main processes 1)
Receptor internalization and degradation [110], 2) Negative regulation by protein
kinase C [111], 3) Tyrosine dephosphorylation by phosphatases [112].
Pharmacological or antibody mediated inhibition of c-kit is widely used to
study the role of this protein in mediating cellular responses. For this study, I used the
drug Imatinib mesylate (STI571 or Gleevec) to inhibit c-kit activation and to confirm
its function in regulating the cellular properties of CPCs. Imatinib was originally
derived from a lead compound discovered to inhibit protein kinase C [113]. Drug
optimizing experiments revealed that the inclusion of an amide group in the phenyl
ring of the lead compound made it an effective inhibitor of the constitutively active
tyrosine kinase BCR-ABL which is associated with chronic myeloid leukemia [114].
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In vitro screening experiments against a panel of related tyrosine kinases highlighted
that this compound is also effective in the inhibition of two other tyrosine kinases,
namely platelet derived growth factor receptor (PDGFR) and c-kit [115]. Since then,
the compound is widely used in the treatment of cancers related to the expression and
over activity of these tyrosine kinases.
Mechanistically, imatinib inhibits the function of its target tyrosine kinases by
blocking the transfer of phosphate from ATP to the tyrosine residues on the enzyme
substrates. It does this by binding to a specific region in the activation site of the
enzyme that is involved in phosphoryl transfer. This binding locks the enzyme in an
inactive confirmation and hence the loss of kinase activity [114].
As imatinib is not a specific inhibitor of c-kit and it also inhibits PDGFR that
is expressed in cardiac cells, using this pharmacological agent in my experiments to
inhibit c-kit could create a concern about the specificity of the inhibitor. I excluded
this limitation by using serum free medium for my experiments which does not
contain the ligand for PDGFR.

Signal Transduction:
In this study, I have also tested the activation of downstream signaling
pathways upon SCF dependent c-kit stimulation. Although my analysis was only
restricted to the activation of only the PI3K-AKT and MEK-ERK pathways,
activation of c-kit can lead to the recruitment and subsequent activation of a number
of downstream mediators (e.g., Grb2, PLD, p38 MAPK, SFK and PLCγ) [116-118].
Figure 3 shows an overview of these signaling molecules that are activated upon c-kit
stimulation. It is important to remember that SCF-dependent activation of c-kit can
lead to the activation of more than one of these pathways. The combination of
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pathways activated and its downstream effects may differ depending on the cell type
and species. A short description on the PI3K-AKT and MAPK pathways is given
below as it is relevant to this study.
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Figure 3: Signal transduction in SCF activated c-kit receptor: The ligand for c-kit,
SCF binds to the c-kit receptor causing receptor dimerization and phosphorylation on
key tyrosine residues. These residues act as a binding site for signal transduction
molecules.
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PI3-Kinase Pathway:
The phosphoinositide 3 kinase or PI3K pathway is considered to be a major
pathway activated upon c-kit stimulation. Studies on SCF mediated c-kit activation in
mast cells, endothelial cells and melanocytes [59, 99, 119, 120] have shown that this
is an important pathway regulating genes that are involved in cell survival,
proliferation, migration and differentiation. There are four major classes of PI3Ks and
the Class I is further divided into class IA and IB. Since much of the published reports
are on class 1A PI3Ks the discussion in this section will be limited to this subtype.
Class IA PI3K has a regulatory subunit p85 and an enzymatic subunit p110 which can
phosphorylate phosphoinositides [121]. p85 has SH2 domains through which it can
bind to phosphorylated tyrosine residues. Upon autophosphorylation on its tyrosine
residues, c-kit binds and activates PI3K either directly [122, 123] through its tyrosine
719 (in murine; Y721 in human) residue [124] or indirectly through the adapter
protein GAB2 [125, 126]. This binding causes a conformational change thereby
activating the enzymatic p110 subunit. PI3K is an intracellular lipid kinase which
translocates to the membrane from the cytoplasm. Upon activation, it binds to and
phosphorylates the 3’ hydroxyl group of the membrane bound phosphoinositol 4, 5
bisphosphate (PIP2) to form phosphoinositol 3, 4, 5 trisphosphate (PIP3). PIP3 binds
to proteins with plekstrin homology (PH) domains [127]. AKT, a serine/threonine
kinase, binds to PIP3 through its PH domain and the kinase PDK1 phosphorylates
AKT making it active. AKT has to be phosphorylated on both a serine and threonine
residue to become fully active [128, 129]. Activated AKT phosphorylates and
regulates many downstream signaling proteins that influence growth and survival
[130]. For example, AKT promotes cell survival by the phosphorylation and
inactivation of the pro-apoptotic protein BAD [111]. Phosphorylation of BAD
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disrupts its interaction with the anti-apoptotic proteins Bcl-XL or Bcl-2 thereby
antagonizing the pro-apoptotic BAX. Inhibition of BAX blocks cytochrome c release
and hence apoptosis [131, 132]. AKT also promotes survival through the
phosphorylation of forkhead transcription factor (FOXO) proteins by subjecting them
to proteosomal degradation. Upon phosphorylation by AKT, FOXO proteins are
retained in the cytoplasm and hence cannot promote the expression of pro-apoptotic
genes [133]. AKT activation has been reported to be involved in the activation of
mammalian target of rapamycin (mTOR) which in turn activates ribosomal S6 kinase
leading to an increase in the transcription of pro-growth and anti-apoptotic genes
[134, 135]. A schematic representation of this pathway is shown in Figure 4.
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Figure 4: Schematic representation of the PI3K-AKT signaling pathway.
Activation of the receptor by the ligand leads to the autophosphorylation of critical
tyrosine residues and binding of the p85 subunit of PI3K through its SH2 domain and
phosphorylation. Activation of PI3K phosphorylates and converts the membrane
bound lipid PIP2 to PIP3 which binds and activates AKT. Activated AKT
phosphorylates several downstream effectors including BAD, mTOR, FOXO
regulating cellular proliferation, migration and apoptosis.
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MAP Kinase Pathway:
The Mitogen Activated Protein Kinase (MAPK) pathway was found to be an
essential pathway promoting proliferation and survival of mammalian cells [136,
137]. It is an important pathway that was found to be activated after c-kit stimulation
in mast cells, melanocytes and hematopoietic cells [138-140]. Although c-kit
activation can stimulate all four types of MAP kinases namely, ERK1/2, p38 MAPK,
ERK5 and JNK, it is the ERK1/2 MAP kinase that has been studied extensively [141,
142]. Studies in melanocytes, endothelial cells and hematopoietic stem cells have
shown that SCF stimulated c-kit leads to the activation of the ERK1/2 kinase
regulating vital cellular properties [37, 143]. The cascade of signaling events starting
from the receptor activation are as follows. Ligand activated c-kit binds to the adapter
protein Grb-2 which binds to the guanine nucleotide exchange factor (GEF) SOS.
SOS interacts with the membrane bound protein Ras and catalyzes the exchange of
Ras bound GDP against GTP. Activated Ras binds to several effector proteins
including B-Raf and activates them. B-Raf activates the dual specificity kinase
MEK1/2 which in turn phosphorylates and activates ERK1/2 [99]. Phosphorylated
ERK1/2 in turn regulates several proteins downstream including retinoblastoma
protein [144], ribosomal protein S6 [145], glycogen synthase kinase 3 (GSK3) [146]
and microphthalmia associated transcription factor (MITF) [147] thereby regulating
cell proliferation, survival, migration and development. A schematic representation of
the MEK-ERK pathway is given in Figure 5.
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Figure 5: Schematic representation of the MEK-ERK signaling pathway.
Activation of the receptor by the ligand leads to the autophosphorylation of critical
tyrosine residues and binding of the adapter protein Grb2. The GEF protein SOS
binds Grb2 and catalyzes the exchange of Ras bound GDP for GTP. Activated GTP
bound Ras binds to and activates B-Raf which in turn phosphorylates and activates
MEK1/2. MEK1/2 is a dual specificity kinase and phosphorylates ERK1/2 on its Thr
and Tyr residues. Erk1/2 has a plethora of downstream effectors including Rb, MITF,
c-fos and c-jun that are responsible for cell cycle regulation, survival and migration of
cells.
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Project Overview:
With all the above evidences, it is clear that CPCs are a group of resident
progenitor cells in the heart that is essential for cardiovascular regeneration both in
animal models and in humans. Also, the activation of c-kit receptor is important for
the proliferation, survival and migration of many c-kit positive cell types under steady
state and stress conditions. Hence, in this work I focused on exploring the role of c-kit
in regulating the different cellular characteristics of CPCs isolated from
endomyocardial biopsy samples from the patients. I hypothesized that c-kit has a role
in the proliferation, apoptosis, migration and differentiation of CPCs. In Aim I, I
demonstrate that activation of the c-kit receptor with its ligand SCF promotes CPC
proliferation, migration and reduces apoptosis under conditions of serum depletion. In
Aim 2, with the use of specific pharmacological inhibitors, I demonstrate the
involvement of the PI3K-AKT and MEK-ERK pathways in mediating the prosurvival, pro-growth and chemotactic effects of SCF-c-kit axis in CPCs. An overview
of this work is depicted in Figure 6.
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Figure 6: Schematic representation of the project: The goal of this project is to
explore the role of c-kit in the proliferation, apoptosis, migration and differentiation of
CPCs. Aim 1 tests the effect of SCF activated c-kit on the above cellular
characteristics and aim 2 tests the involvement of PI3K-AKT and MEK-ERK
pathways in mediating the SCF mediated cellular effects in CPCs.
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CHAPTER II
ROLE OF C-KIT IN THE GROWTH, MIGRATION AND DIFFERENTIATION OF
HUMAN CARDIAC PROGENITOR CELLS
Introduction:
Cardiovascular diseases are the leading cause of morbidity and mortality in the
Western World [148]. Myocardial ischemia or infarction that occurs due to
compromised blood supply to the heart results in extensive tissue damage and loss of
functional cardiomyocytes. This results in cardiac hypertrophy and ventricular
dilatation contributing to heart failure with a poor clinical prognosis [149, 150]. In
this context, several attempts have been made to regenerate the injured myocardium
with the help of different stem/progenitor cell populations that are present exogenous
or endogenous to the heart. Exogenous sources including hematopoietic
stem/progenitor cells [91], embryonic stem cells [151] and induced pluripotent stem
cells [152] have been used to regenerate the injured myocardium, although to a
variable extent. Endogenously, at least seven different types of cardiac progenitor
cells have been identified and used to regenerate the dead tissue of the myocardium.
They are the c-kit+ CPCs, Sca1+ CPCs, side population (SP) cells, cardiosphere
derived cells (CDCs), cardiac resident colony forming unit fibroblasts, cardiac
mesangioblasts and Isl1+ cells [4, 7-19] [153, 154]. Among these cells, only two of
them were tested clinically on humans. CADUCEUS trial injected autologous CDCs
to patients with left ventricular dysfunction after myocardial infarction (MI)
and found that these cells are safe and capable of regenerating the infarcted
myocardium [155]. In SCIPIO, intra coronary injection of patient derived c-kit+ CPCs
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promoted cardiac regeneration in heart failure patients [6]. While the CDCs contain
heterogeneous population of cells comprising of c-kit+ cells, CD90+ (Thy1) cells,
endothelial cells (CD31+), endothelial progenitor cells (CD34+) that are negative for
pan-hematopoietic marker CD45 [15, 156, 157], the SCIPIO trial injected only the ckit+ CPCs and found significant clinical improvement in the injected patients. The
discovery of endogenous CPCs that has the potential to regenerate the injured
myocardium opened new avenues of cardiac regenerative therapy. The use of CPCs in
cardiac regeneration also led to the initiation of several studies aimed at finding
methods and key proteins that are essential to optimize the efficiency of cellular
transplantation. Although these CPCs provide excellent clinical improvement after
transplantation, there are many challenges identified in the process. These cells have
poor survival and nearly 95% of the cells viable at 5 minutes after injection are lost
within a week after transplantation [34]. Also poor engraftment and homing of these
cells are a major concern [34, 158-160]. A number of studies identified several
cytokines, enzymes and signaling molecules and demonstrated enhanced survival and
better homing of CPCs by targeting them [161, 162]. This area also intrigued us to
find ways to improve the therapeutic outcome of CPC transplantation. In light of the
essential role of c-kit in other cell types as discussed in chapter 1 of this manuscript, I
studied the role of c-kit activation in regulating the growth, survival, migration and
differentiation of CPCs. Even though studies on c-kit have established the antigen as a
pro-survival, anti-apoptotic, mitogenic and pro-migratory agent in a variety of cell
types [35-37, 40, 53, 163-165], the role of c-kit in CPCs remains elusive. Hence to my
knowledge this is the first attempt to characterize the role of this receptor protein in
the regulation of cellular properties in CPCs.
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Materials and Methods:
Isolation and culture of c-kit+ human cardiac progenitor cells
Isolation and characterization of c-kit+/lin- human CPCs were done as
described previously [7, 166]. Briefly, atrial appendages obtained from ischemic
cardiomyopathy patients undergoing endomyocardial biopsy were enzymatically
digested and cultured in complete growth medium (Ham’s F12 media containing 10%
fetal bovine serum, 10 ng/ml bFGF [PeproTech], 0.005 U/ml human erythropoietin
[Sigma], and 0.2 mM L-glutathione [Sigma]). Media was changed every two days.
MACS kit (Miltenyl Biotec) was used to enrich for c-kit+/lin- CPCs following the
manufacturer’s instructions and as described previously [166]. Ham’s F12 media with
0.2 mM L-glutathione was used as assay medium for all the experiments unless
mentioned otherwise.

Cell growth and viability
Manual cell counting or PrestoBlueTM (Invitrogen) was used to assess cell
growth and viability. For manual cell counting, approximately 50,000 cells were
plated per well of a 24-well plate. CPCs were then serum starved for 24 hr and treated
with or without 100 ng/ml SCF in serum free media. For bFGF and VEGF treatments,
CPCs were incubated with 50 ng/ml bFGF (Peprotech) or 20 ng/ml VEGF
(Invitrogen) either alone or in combination with SCF as indicated. After 3 days of
growth factor treatment, cells were trypsinized and counted using a hemacytometer.
For measurement of cell viability using PrestoBlueTM, 10,000 CPCs were plated per
well of a 96-well plate. When indicated, CPCs were treated with 0.5 µM imatinib
mesylate (Cayman Chemicals) for 2 hr prior to SCF treatment. PrestoBlueTM cell
viability assay was performed 72 hr post-growth factor treatment according to the
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manufacturer’s instructions. Briefly, the 10x reagent was mixed with an appropriate
volume of serum free medium, added to the cells and incubated at 37 ºC for an hr. The
viability was assessed by measuring the fluorescence at Ex/Em 560/590 nm.

BrdU assay
Approximately 10,000 cells per well were plated on a 96-well tissue culture
plate. Cells were serum-starved for 24 hr followed by treatment with 20 µM BrdU for
24 or 72 hr in the presence or absence of SCF in the assay medium. After BrdU
labeling, cells were fixed and immunostained using anti-BrdU antibody (at 1 in 1,000;
Sigma-Aldrich #B8434) and Alexa555-conjugated secondary antibody (at 1 in 1,000;
Invitrogen). Images were captured using EVOS® FL Cell Imaging System (Life
Technologies), and the BrdU-positive cells were counted manually.

Caspase assay
Apo-ONE® Homogeneous Caspase-3/7 Assay kit (Promega) was used to
measure the caspase activity in CPCs according to the manufacturer’s instructions.
Briefly, approximately 10,000 CPCs were plated per well. The next day, the medium
was changed to serum free media or same media containing SCF. After 3 days of SCF
treatment, the caspase activity in the cells was measured by adding the pro-fluorescent
substrate and reading the fluorescence at Ex/Em 499/521 nm. The values were
normalized to the untreated control.

Oxidative stress by DMNQ and H2O2
For DMNQ experiments, approximately 10,000 human c-kit+ CPCs per well
were plated on a 96-well tissue culture plate. On the next day, cells were treated with
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100 ng/ml SCF in serum free media. For the imatinib treatment groups, cells were
treated with 0.5 µM imatinib for 2 hr prior to the SCF treatment. On the second day,
CPCs were subjected to 8 µM DMNQ (dimethoxy-naphthoquinone; Sigma) treatment
in the groups indicated. After 3 days of DMNQ treatment, cell viability was assessed
using PrestoBlueTM. For H2O2 experiments, approximately 10,000 cells per well were
plated on a 96-well tissue culture plate. On the next day, cells were treated with 100
ng/ml SCF or 10 µg/ml insulin (Gibco) in serum free media. On the following day,
CPCs were subjected to 0.5 mM H2O2 (EMD Chemicals) treatment for 1 hr. Cell
viability was assessed 3 days later using PrestoBlueTM.

Western blot analysis
Cells were harvested with Laemlli buffer and heated for 10 minutes at 100 ºC.
Protein concentration was estimated using bicinchoninic acid (BCA) assay kit
purchased from Thermo scientific following manufacturer’s instructions. Before
loading the samples on the gel, 3 µl of β-mercaptoethanol was added per 100 ul of
sample and heated for 3 minutes at 100 ºC. Cell lysate (25 or 50 μg of protein) was
loaded on 4-20% Tris-Glycine gel and separated by electrophoresis. The separated
proteins were transferred to a PVDF membrane, blocked with 5% skim milk or 5%
bovine serum albumin for 1 hr followed by probing with primary antibody overnight
at 4 ºC. The blot was then incubated with HRP-conjugated secondary antibody for 1
hr and developed using Amersham ECL Prime Western Blotting Detection Reagent
(GE Healthcare). Primary antibodies used were anti-c-kit (1 in 500; abcam #32363),
anti-phospho c-kit (Y703; 1 in 500; Cell Signaling #3073P) and anti-α-tubulin (1 in
3,000; Sigma #T6074).
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In vitro cell migration
Boyden chambers containing transwells (24-well plate format) with 8 µm pore
size were purchased from Corning. Typically, 30,000 – 40,000 cells were plated in the
upper chamber of the transwell. After 24 hr, the medium in the upper chamber was
changed to assay medium and bottom chamber was filled with the same medium
alone or medium containing 100 ng/ml SCF. For inhibition of c-kit activity, cells were
pre-treated with 0.5 µM imatinib for 2 hr prior to the SCF treatment. After 24 hr, the
cells migrated to the lower surface of the transwell membrane were fixed with 3.7%
formaldehyde for 10 minutes, and the cells still remaining on the upper chamber were
scraped off. The fixed cells were then permeabilized with 0.25% Triton X-100 in PBS
for 10 minutes followed by incubation with 50 μg/ml propidium iodide solution for
10-15 minutes. Images were acquired using EVOS® FL Cell Imaging System (Life
Technologies), and the number of migrated cells was quantified using the NISElements (version 4.2) software.

Clonogenicity assay:
Individual cells were plated on a 96 well plate by limiting dilution method.
Briefly, CPCs were diluted with appropriate volume of growth media to achieve 1 cell
per 100 μl of medium and plated on a 96 well plate. Individual cells were screened
and treated with 100 ng/ml SCF or left untreated. Medium was replacement every 5
days and individual CPCs were followed up for 14 days for the formation of clones.
The percentage clonogenicity was calculated from the number of individual cells
tracked to the cells among them that formed clones.
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Dexamethasone induced differentiation of CPCs:
Approximately 100,000 CPCs were plated on a 12 well plate in growth media.
24 hours after plating the cells, time 0 control (undifferentiated) was harvested with
TRIzol following the manufacturer’s instructions. For the remaining cells, the media
was changed to DMEM with 5% fetal bovine serum containing 10 nM dexamethasone
or 100 ng/ml SCF or a combination of both or DMSO (control). Medium was
replaced every alternate day up to 2 weeks (hCPCs) or 4 weeks (mCPCs) at the end of
which the cells were harvested with TRIzol and stored at -80 0C until required. RNA
was isolated from the samples stored at -800C using Qiagen’s RNEasy Mini Kit (Cat.
74106) following manufacturer’s protocol and the concentration was measured using
a nanodrop. 250 ng of RNA was used to perform cDNA synthesis using AffinityScript
Multiple

Temperature

Reverse

Transcriptase

kit

(Cat.

600105)

following

manufacturer’s instructions. Real-time PCR for different markers listed was
performed with the harvested samples in a 10 μl reaction using the primers listed
below, SYBR Green PCR master mix and Stepone Plus real-time PCR machine
(Applied Biosystems). The results were analyzed using the Stepone software.

Lentivirus production and transduction
The lentivirus carrying mCherry or FLAG-tagged murine c-kit was produced
by using the ViraPowerTM Lentiviral Expression System and pLenti6-V5 vector
(Invitrogen) according to the manufacturer’s instructions. Virus was concentrated
using the Lenti-X Concentrator (Clontech) and was stored at -80 ºC until its use. On
the day of the experiment, CPCs were transduced with complete medium containing
either mCherry or c-kit virus and 6 µg/ml polybrene (Sigma). On the following day,
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the media was replaced with fresh complete media. Cells were cultured for 5 days to
allow expression of mCherry or c-kit prior to being used for the experiments.

Statistical analysis
Statistical analysis was performed by Mann-Whitney U test using SPSS ver.
17 software. Data are presented as mean ± SEM. SEM is an estimate of the precision
of mean and often used in scientific studies. P value of <0.05 was considered as
statistically significant.

Results:
c-Kit+ CPCs express functional c-kit receptors:
First, I tested to confirm if human CPCs express functional c-kit receptors.
Western blot analysis confirmed expression of c-kit in CPCs, and treatment of CPCs
with the c-kit ligand SCF increased the level of tyrosine phosphorylation of the c-kit
receptor (Figure 7). In addition, pre-treatment of the cells with the c-kit inhibitor,
imatinib abolished the SCF-induced phosphorylation of the receptor as expected
(Figure 7). This indicates that human CPCs express functional c-kit receptors that can
be activated by its ligand SCF.
c-Kit activation promotes growth and survival of human c-kit+ CPCs
I then tested if SCF/c-kit signaling can act as a pro-growth or pro-survival
pathway when CPCs are subjected to conditions of stress. I first examined if serum
starvation could be an ideal condition to study the pro-survival or pro-growth effect of
SCF by growing CPCs under different degrees of serum starvation in the presence or
absence of the kit ligand SCF. I found that when CPCs are grown in conditions
containing less than 10% serum, activation of c-kit increased the number of viable
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CPCs compared to the untreated control (data not shown). I used serum free media for
subsequent experiments to avoid the effect of known and unknown growth factors
present in the serum which may influence CPC survival or growth. In the next step, I
tested if c-kit activation could rescue the CPCs grown under serum starvation by
treating them with or without SCF and measuring the cell number on each day until 5
days post-SCF treatment (Figure 8A). Compared to the vehicle control, SCF treatment
resulted in a significantly greater number of cells starting at day 3 and up to day 5.
Moreover, the pro-survival or pro-growth effect of SCF on CPCs was dosedependent, and its effect plateaued at 100 ng/ml (Figures 8B and C). Hence, 100
ng/ml concentration of SCF was chosen for all the subsequent experiments. Next, I
compared the effect of SCF with those of other growth factors, including vascular
endothelial growth factor (VEGF) and basic FGF (bFGF), either alone or in
combination with SCF, in CPCs grown under serum starvation. Although the prosurvival or growth effect of SCF was comparable to that of bFGF in CPCs (Figure
8D), I did not find any additional or synergistic effect when cells were treated with a
combination of growth factors (Figure 6D), suggesting that they share similar
downstream signaling pathways. To further confirm these findings, I overexpressed ckit (or mCherry as a control) in human CPCs using lentivirus and subjected the cells
to serum starvation in the presence or absence of SCF (Figure 9A). As expected,
overexpression of c-kit resulted in a further increase in the number of viable cells
when treated with SCF (Figure 9B). Such effect was abolished by pre-treatment of
cells with imatinib, the c-kit inhibitor, suggesting that the effect of SCF on CPCs is
indeed mediated through c-kit receptor (Figure 9B). These results together indicate
that SCF-mediated activation of c-kit enhance survival or growth of CPCs cultured
under serum starvation.
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Figure 7: Activation of c-kit by SCF in human c-kit+ CPCs. CPCs were either
treated with SCF (100 ng/ml) alone for 10 minutes or co-treated with imatinib. Cell
lysate was analyzed by Western blot for the indicated proteins. p-c-kit,
phosphorylated (i.e., activated) c-kit (n=2).
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Figure 8: c-Kit activation promotes growth of human c-kit+ CPCs under serum
starvation. A, The effect of SCF on cell growth. CPCs were serum starved for 24 hr
and treated with SCF. The number of cells remaining was counted at the indicated
time points (n=1). B, Dose-response relationship between SCF and CPC growth.
CPCs were serum starved for 24 hr followed by treatment with varying concentrations
of SCF, and the number of cells remaining after 3 days was determined (n=3). C,
Representative DAPI nuclear staining images of SCF-treated CPCs described in panel
C. D, Comparison of SCF with bFGF and VEGF in promoting growth of CPCs. CPCs
were serum starved for 24 hr and treated with SCF, bFGF, or VEGF either
individually or in combination, and the number of cells were counted on days 5 and 9
of treatment (n=2). Values are presented as mean ± SEM. *, p<0.05.
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Figure 9: c-Kit over expression further increases CPC survival under serum
starvation.

A, Human c-kit+ CPCs were transduced with lentivirus expressing

mCherry (control) or c-kit. Cell lysates were obtained at 4 days post-viral transduction
and immunoblotted for c-kit and α-tubulin (loading control). B, mCherry or c-kitexpressing CPCs were serum starved for 24 hr and cultured for 3 days in the presence
(+) or absence (-) of SCF and/or imatinib as indicated. Cell viability was assessed
using PrestoBlueTM as described. Values were normalized to the DMSO (vehicle)
control (n=3). Values are presented as mean ± SEM. *, p<0.05.
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c-Kit activation fails to rescue CPCs from oxidative stress
I then tested if SCF can also prevent cell death induced by other stress
conditions, such as oxidative stress, in CPCs. For this, CPCs were pre-treated with
SCF for 24 hours followed by treatment with an oxidative stress inducer, dimethoxynaphthoquinone (DMNQ) or H2O2. Of note, DMNQ is a quinone that induces
superoxide anion formation by redox cycling [167], whereas H2O2 undergoes Fenton
reaction in the presence of iron and produces reactive oxygen species, causing cell
injury and death [168]. As shown in Figure 10A, DMNQ treatment led to a significant
decrease in the number of cells. However, pre-treating the cells with SCF failed to
prevent the cell death induced by DMNQ treatment (Figure 8A). Correspondingly,
SCF treatment of CPCs was not able to prevent or attenuate the cell death following
H2O2-induced oxidative stress (Figure 10B). Similar results were obtained upon pretreating CPCs with varying concentrations of SCF ranging from 10 ng/ml to 200
ng/ml (data not shown). In contrast, insulin pre-treatment (a positive control) was able
to rescue CPCs from H2O2-induced oxidative stress (Figure 10B). Taken together,
these results demonstrate that while SCF-induced activation of c-kit promotes survival
of CPCs grown under serum depletion, it does not recue CPCs subjected to oxidative
stress.
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Figure 10: c-Kit activation does not rescue CPCs from oxidative stress. A, Human
c-kit+ CPCs were pre-treated with SCF for 24 hr in serum free media and subjected to
8 µM DMNQ treatment (n=2). B, Cells pre-treated with or without SCF received 1 hr
treatment in 0.5 mM H2O2, followed by media change with or without SCF. Insulin
was used as a positive control. Cell viability was assessed after 3 days using
PrestoBlueTM. *, p<0.05 compared to the untreated control, #, p<0.05 compared to the
H2O2 only control. NS, no statistical significance (n=2). Values presented are mean ±
SEM.
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c-Kit activation leads to increased proliferation of CPCs
In order to test whether the observed increase in the number of viable cells
was due to the mitogenic effect of SCF/c-kit signaling, I performed a BrdU labeling
assay [169]. For this assay, I cultured the cells under serum starvation in the presence
or absence of SCF and incubated them with BrdU for 24 hr starting at different time
points. When compared to the control, SCF increased the BrdU labeling index in
CPCs during days 2 and 3 of the treatment, suggesting that SCF treatment promotes
proliferation in CPCs (Figure 11A). However, the difference between the two
treatment groups did not reach statistical significance. Next, I treated the cells with
BrdU continuously for 3 days with or without SCF. With continuous BrdU supply and
SCF treatment, the percentage of BrdU-positive CPCs increased to 10.2 ± 3.9% (SCFtreated group) from 3.9 ± 3.4% (untreated control group), significantly raising the rate
of proliferation by more than 2-fold (Figure 11B). This demonstrates that SCF acts as
a mitogen for CPCs under conditions that restrict their growth.

c-Kit activation reduces apoptosis of CPCs under serum starvation.
I then examined if SCF besides acting as a mitogen, can reduce apoptosis of
CPCs grown under serum depletion conditions. For this purpose, I measured the
activity of caspases 3 and 7 in CPCs after growing them under complete serum
depletion for 3 days in the presence or absence of SCF. As shown in Figure 11C c-kit
activation with SCF resulted in a significant reduction of caspase activity compared to
the untreated control. Moreover, inhibiting c-kit with imatinib partially abolished this
reduction in caspase activity (Figure 11C). These studies suggest that SCF dependent
c-kit activation in addition to acting as a mitogen, also has an anti-apoptotic role in
CPCs.
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Figure 11: c-Kit activation induces proliferation and decreases apoptotic cell
death in CPCs. Human c-kit+ CPCs were serum starved for 24 hr and labeled with
BrdU in the presence or absence of SCF for 24 hr only for the indicated day (A, n=1)
or continuously for 3 days (B, n=2). Cells were stained with anti-BrdU antibody, and
the positive cells were expressed as the percentage of total nuclei. C, CPCs were
grown in serum free media for 3 days. Activities of caspases 3 and 7 were measured
and normalized to the untreated control (n=3). Imat – Imatinib. Values presented are
mean ± SEM. *, p<0.05.
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N = 3,

c-Kit activation promotes migration of CPCs
For successful engraftment of the donor cells following transplantation,
homing of the CPCs to the recipient myocardium and the injured area is required.
Studies have shown that c-kit expression is important for the migration of several ckit+ cell types including melanocytes [52], human umbilical vein endothelial cells
(HUVEC) [59] and germ cells [170]. Hence I tested if the SCF-c-kit axis contributes
to the migration of CPCs. To test this, I implemented the Boyden chamber and used
SCF as a chemo attractant. I found that SCF significantly promoted the migration of
CPCs and was comparable to VEGF (Figures 12A and B), which has previously been
shown to promote migration of CPCs [161]. To further confirm the result, I
overexpressed c-kit in CPCs with mCherry as a control using lentivirus and performed
the same migration assay. As expected, upon c-kit overexpression and SCF treatment,
the number of migrated cells was further increased compared to the mCherryexpressing control CPCs. Furthermore, inhibiting c-kit with imatinib abolished the
pro-migratory effect of SCF/c-kit signaling observed (Figure 12C) suggesting that the
chemotactic effect of SCF on CPCs are indeed mediated through the activation of ckit receptor.
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Figure 12: c-Kit activation promotes migration of CPCs. Boyden chamber assay.
Human c-kit+ CPCs were plated in the upper chamber, and the indicated growth
factors were used as a chemoattractant in the lower chamber. After 24 hr, the migrated
cells were fixed, stained with propidium iodide, and counted. A, Comparison of the
pro-migratory effect between SCF and VEGF (n=1). B, Representative images
showing the cells migrated towards the indicated growth factors. C, CPCs transduced
with lentivirus expressing mCherry (control) or c-kit were compared for their
chemotaxis towards SCF in the presence (+) or absence (-) of 0.5 µM imatinib (n=3).
Values presented are mean ± SEM. *, p<0.05.
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c-Kit activation does not play an overt role in the differentiation of CPCs
One of the critical properties of stem/progenitor cells is their inherent ability to
differentiate into cell types of multiple lineages [171]. It has been shown that c-kit+
CPCs are multipotent and can differentiate in to cardiomyocytes, smooth muscle
cells, fibroblasts and endothelial cells in vitro and in vivo [4, 5, 20]. I tested if the
activation of c-kit contributes to the differentiation of CPCs (Figure 13). To test this,
human CPCs were induced to differentiate with 10 nM dexamethasone (dex)
treatment for 2 weeks and analyzed the expression of various endothelial (KDR),
cardiogenic (Troponin-T, connexin-43, GATA4), mesenchymal/fibroblast (FSP1,
DDR2, Vimentin) and smooth muscle cell markers (αSMA) (Figure 13A). We
observed an increase in the mRNA expression levels of KDR and troponin-T in one
sample (Patient 1) and DDR2 and FSP-1 in the other (Patient 2) when compared to
the untreated control group. Also there was a decrease in the mRNA expression of
other markers after two weeks of dex treatment. However, activation of the c-kit
receptor with SCF did not significantly change the mRNA expression levels for most
of the markers when compared to the untreated control group. As shown in Figure
13A, the results were variable between biological replicates and in most cases did not
reach statistical significance when compared to the untreated control. In order to
account for the variability between biological replicates, our group also tested the
activation of c-kit in the differentiation of mouse CPCs (Figure 13B). Interestingly,
we found an increase in a number of cardiogenic markers including ANP, BNP,
αMHC, βMHC, troponin-I and troponin-T, but other lineage markers did not change
significantly compared to the untreated control. Also, adding SCF alone or in
combination with dex did not additionally contribute to the differentiation of CPCs.
Considering that dex treatment was not able to induce robust differentiation with both
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human and mouse CPCs, my aim to test the contribution of c-kit activation to the
differentiation of CPCs remains inconclusive.

Activation of c-kit does not affect the clonogenicity and pluripotency of CPCs
c-Kit is widely known as a stem/progenitor cell marker but the contribution of
c-kit activation to the clonogenicity and pluripotency of the stem/progenitor cells is
not clear. To test this idea, first, I checked if c-kit activation can influence the
clonogenicity of CPCs (Figure 14A). While we found that SCF dependent c-kit
activation could promote the clonogenicity of CPCs cultured in the growth media
containing 5% serum, the results were not reproducible. Similarly, my attempt to
analyze the expression of pluripotent factors (Oct4, Nanog, Klf4, SOX2) upon c-kit
activation did not yield significant results (Figure 14B). The expression of the
pluripotent factors except for Klf4 at the mRNA level was undetermined.
Additionally, c-kit activation or dex treatment did not change the klf4 expression
significantly compared to the untreated control. In summary, my findings suggest that
activation of c-kit does not affect the clonogenicity and pluripotency of CPCs.
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Figure 13: c-Kit activation does not play a role in the differentiation of CPCs.
Dexamethasone induced differentiation. A. Human c-kit+ CPCs were treated with 10
nM dexamethasone (Dex) or vehicle (Untreated) or SCF or Dex+SCF continuously
for 2 weeks and analyzed for the expression of different markers as indicated. B.
Mouse c-kit+ CPCs were treated with 10 nM dexamethasone (Dex) or vehicle
(Untreated) or SCF or Dex+SCF continuously for 4 weeks and analyzed for the
expression of different markers as indicated.
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Figure 14: c-Kit activation does not affect the clonogenicity and pluripotency of
CPCs. A. Individual human c-kit+ CPCs in growth media with different serum
concentrations were treated with vehicle (control) or SCF for 2 weeks and analyzed
for clonogenic cells (n=2). B. Patient derived c-kit+ CPCs were treated with 10 nM
dexamethasone (Dex) or vehicle (Control) or SCF or Dex+SCF continuously for 2
weeks and analyzed for the mRNA expression of klf4, nanog, oct4 and sox2. Only
klf4 was detectable (n=2). Values presented are mean ± SEM. *, p<0.05.
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Discussion:
In the study presented here, I have shown that activation of c-kit promotes the
growth, survival and migration of CPCs cultured under serum deprived conditions. In
addition, the data shows that the pro-growth/survival and pro-migratory effect is even
more pronounced when c-kit is overexpressed and the same is abolished when c-kit
activation is suppressed with imatinib. The results of this study imply that the SCF/ckit signaling pathway in CPCs can be exploited to overcome one of the major
problems in the current field of cardiac cell therapy: poor survival and engraftment of
the transplanted cells.
Although this is the first study to establish the role of c-kit in the regulation of
growth, survival and migration of CPCs, the present findings are consistent with
previous studies that have emphasized the importance of c-kit activation in cardiac
remodeling after MI. For example, a study by Xiang et al indicated that
cardiomyocyte specific overexpression of SCF can enhance cardiac repair, heart
function and the overall survival of the animal after myocardial infarction [172]. The
overexpression of SCF in the cardiomyocytes significantly reduced cellular apoptosis
in the peri-infarct area. The SCF overexpression was accompanied by a decreased end
diastolic volume and better cardiac function compared to the control groups.
Activation of the SCF-c-kit axis also attenuated MI-induced hypertrophy and
significantly increased the capillary density in the peri-infarct area compared to the
controls indicating that the pathway promotes angiogenesis and cardiac repair.
Interestingly, SCF overexpression also increased the recruitment of endothelial
progenitor cells in the peri-infarct area demonstrating the regenerative capacity of the
activated SCF-c-kit pathway in an injured heart. Another study by Yaniz-Galende and
colleagues substantiated the

above findings by demonstrating that
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adenovirus-

mediated gene delivery of the membrane-bound form of SCF to the myocardium can
provide a long-term improvement in cardiac structure and function in an animal
model of myocardial infarction (MI) by the recruitment of cardiac c-kit+ population at
1 week post-MI [173]. These reports support the findings of the study presented here
and suggest an important role for SCF dependent c-kit activation in promoting the
migration and survival of cells that are required for cardiac repair.
The poor survival of the precursor cells can at least in part be attributed to its
poor homing capacity affecting the outcome of transplantation cell therapy. Several
factors may play a role in determining how efficiently the implanted cell can home to
its intended target site. For example, migration of the cells can be affected by the
route of administration of the cells. Inefficient migration has been identified as a
major problem especially when the cells are delivered via the intracoronary route, as
cells must transverse through the endothelial barrier to enter into the interstitial space
and migrate towards the infarcted area. In a recent study, our laboratory has shown
that greater than 60% of the injected cells are lost during the first 5 min of
intracoronary injection of CPCs [34], suggesting that the majority of the cells are
immediately washed away by the coronary blood flow. Moreover, during the ensuing
24 hour, greater than 85% of the cells remaining at 5 min are further lost [34]. Such
rapid loss of the transplanted cells can be explained, at least in part, by inefficient
homing and engraftment of the cells, which represents a major hurdle in the current
CPC therapy. One of the findings in the present study is that activation of c-kit by its
ligand SCF can stimulate migration/chemotaxis of human patient-derived CPCs. This
implies that augmentation of the SCF/c-kit signal pathway represents an attractive
mean to enhance CPC homing and engraftment in the context of cardiac cell therapy.
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Previous studies have shown that the progenitor cells require a combination of
cytokines for optimal growth. For example, a study by Lowry et al have shown that
SCF in combination with colony-stimulating factor-1 (CSF-1), granulocyte CSF (GCSF), granulocyte-macrophage CSF (GM-CSF), interleukin -1α (IL-lα), and IL-3
stimulated optimal colony growth of the murine hematopoietic progenitor cells [174].
In the same system, addition of SCF or the cytokine cocktail alone did not produce
significant colonies suggesting that SCF has the ability to synergize with a
combination of growth factors and stimulate the growth of the hematopoietic colonies
[174]. Also in another study by Gabrilov et al, addition of SCF or basic FGF (bFGF)
alone to myeloid progenitor cells did not promote its growth. But, when they are
added in combination with GM-CSF, the growth of the progenitor cells was
significantly increased. The effect was further enhanced when a combination of SCF
and bFGF was added to GM-SCF further supporting the synergistic action of SCF
with other growth factors [175]. Supported by the synergy of SCF in other progenitor
cell populations, I tested if SCF has a combinatorial effect with bFGF or VEGF in
augmenting the growth/survival of CPCs. The results of this study indicate that there
is no additive effect of SCF with bFGF/VEGF in CPCs implying that these growth
factors act through a common signal transduction pathway in CPCs.
The findings of the present study demonstrate that activation of c-kit leads to
increased proliferation and survival and induce migration/chemotaxis in human
patient-derived CPCs grown under serum depletion. Serum starvation has been
demonstrated to affect cell survival and growth by modifying proteins that regulate
cell cycle and apoptosis. For example, culturing human ovarian carcinoma cell line
under serum depleted conditions was found to arrest the cells in G1 phase of the cell
cycle by the suppression of cyclin dependent kinases 2 and 4 (CDK 2, CDK4) that are
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required to drive the cells from G1 to the S phase [176]. Interestingly, c-kit activation
with SCF was found to release the cells from G1 arrest by upregulating the cell cycle
protein cyclin D3 via the PI3K-AKT pathway [134]. The function of cyclin D3 is to
phosphorylate and inactivate the retinoblastoma protein (Rb) that prevents the cells
from progressing to the S phase [177]. In addition to arresting the cells at G1, serum
starvation has been shown to induce apoptosis by enhancing the expression of proapoptotic proteins BAX and PUMA [178] or by activating the apoptosis initiator
protein, Ataxia telangiectasia mutated (ATM) [179]. In contrast, c-kit activation has
been found to upregulate the expression of the anti-apoptotic proteins Bcl-2 and BclXL [180]. Bcl-2 functions to prevent the activation of the pro-apoptotic protein BAX
thereby suppressing programmed cell death [181]. Though the presented study did not
test the contribution of these effectors in the SCF-c-kit mediated survival/growth of
CPCs, in support of the above discussed studies, it is tempting to speculate a similar
mechanism is responsible for the pro-survival/growth response observed after c-kit
activation in CPCs cultured in nutrient deprived conditions.
This study also presents that in divergence to its role under serum deprivation,
c-kit activation is not sufficient to rescue the cells that are subjected to DMNQ/H2O2
induced oxidative stress. Studies in HSCs have shown that ATM and the Forkhead
family of transcription factors (FOXO) are essential for the anti-oxidative stress
response in progenitor cells. Loss of either of the proteins has been reported to cause
accumulation of reactive oxygen species (ROS) resulting in a defective HSC pool
leading to marrow failure [182, 183]. Moreover, the activation of certain signaling
cascade like the PI3K-AKT pathway phosphorylates and inactivates FOXO
transcription factors [184]. In light of the above reports, it is tempting to speculate that
the activation of c-kit in CPCs inactivates the FOXO proteins through a similar
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mechanism thereby suppressing the anti-oxidative stress response. When the cells are
challenged with drug induced oxidative stress in addition to serum starvation, the
inherent ant-oxidative stress mechanism may be overwhelmed and not sufficient to
protect the cells. It is also possible that the SCF-c-kit signaling cascade may inhibit
ATM thereby increasing the sensitivity of CPCs to drug induced oxidative stress.
The cellular effects of c-kit activation upon SCF stimulation are produced by
the dimerization and autophosphorylation of the receptor leading to the activation of
signal transduction pathways that mediates the biological effects. The findings
presented here invite an interesting question about the molecular pathways that are
involved in mediating the pro-survival and chemotactic effects of SCF-c-kit axis
which is addressed in the next chapter.
In conclusion, with the results of this study it is evident that the activation of
the c-kit receptor is involved in regulating proliferation, apoptosis and migration of
CPCs. Targeting c-kit to manipulate the properties of CPC has the potential to lead to
better treatment strategies and improve the therapeutic outcome of CPC
transplantation.
……………………

……………………
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CHAPTER III
MOLECULAR PATHWAYS INVOLVED IN SCF-C-KIT MEDIATED HUMAN
CARDIAC PROGENITOR CELL SURVIVAL OR GROWTH AND MIGRATION

Introduction:
The pleiotropic cellular responses of SCF dependent c-kit activation are
mediated via the activation of multiple signaling pathways downstream. These
pathways include the PI3K-AKT [119, 124], p38MAPK [138, 185], MEK-ERK [139,
141], SFK [141, 186], phospholipase C [187] and JAK/STAT [126, 185] pathways.
Among these, the PI3K-AKT and the MEK-ERK pathways often represent the major
pathway activated upon c-kit stimulation in a wide variety of cell types [139, 188,
189]. A detailed description of the PI3K-AKT and MEK-ERK pathways is given in
the section under signal transduction discussed in Chapter I of this manuscript.
Briefly, when the growth receptor is phosphorylated on their intracellular tyrosine
domains after ligand binding the PI3K translocates and binds to the receptor directly
or indirectly through the receptor substrates via the SH2 domain present in their
regulatory subunit. This binding causes allosteric activation of the enzyme which
leads to the phosphorylation of PIP2 to PIP3. As discussed earlier, PIP3 can activate
AKT initiating the signaling cascade. Similarly, ligand activated growth receptor
binds to the adapter protein Grb-2 which binds to SOS. SOS interacts with the
membrane bound protein Ras and catalyzes the exchange of Ras bound GDP against
GTP. Activated Ras binds to several effector proteins including B-Raf and activates
them. B-Raf activates MEK1/2 which in turn phosphorylates and activates
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ERK1/2 initiating the signaling cascade [20].
Since the discovery of the c-kit receptor and its ligand SCF, several different
gain of function mutations of c-kit that are associated with a number of diseases have
been identified. A majority of these mutations involve the residues in the
juxtamembrane region or in the second kinase domain [190]. For example,
substitution of aspartic acid 816 (in humans) with valine (D816V) is a common gain
of function mutation associated with c-kit. This mutation results in an increased
kinase activity and constitutive phosphorylation on tyrosine residues independent of
ligand binding, leading to cellular transformation [191, 192]. Several studies have
reported that such gain of function mutation of c-kit cause constitutive activation of
the PI3K-AKT and MEK-ERK pathways, contributing to uncontrolled proliferation
and survival of the transformed cells [188, 193]. These pathways are not only
involved in tumorigenesis but also found to be the key players in mediating the
physiological functions in c-kit+ cell types. They are identified to play an important
role in regulating the proliferation, migration and survival in melanocytes [36, 194],
mast cells [139, 195], endothelial cells [59] and hematopoietic stem cells [196]. It has
been reported that these two pathways are dependent on each other and the inhibition
of the PI3K-AKT pathway leads to the inhibition of the MEK-ERK pathway, at least
in melanocytes [120]. In the same cells, inhibition of these two pathways with
pharmacological inhibitors has resulted in cellular apoptosis, indicating the
indispensable role of the above two pathways in cell survival [120].
The significance of the activation of any signaling molecule in a cell system
can be elucidated using specific pharmacological inhibitors for the molecule.
Similarly, pharmacological inhibition of the PI3K-AKT and MEK-ERK pathways can
be used to analyze the involvement of these pathways in mediating the cellular
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responses. In this study, I used Wortmannin the inhibitor of PI3K and PD98059 the
MEK inhibitor to validate the participation of these two pathways downstream of c-kit
activation.
Wortmannin is a steroid metabolite isolated from the fungi Penicillium
wortmannii [197]. It is a specific inhibitor of PI3K at the physiological pH [198]. A
detailed description of the PI3K-AKT signaling cascade is given under the signal
transduction section of chapter 1. Under physiological pH, Wortmannin binds
covalently to p110 subunit of PI3K [198]. However, when the pH is increased to 8.5
and beyond, it could also bind to the regulatory subunit. It was also found to bind nonspecifically to other related kinases at micromolar concentration. Substrates of PI3K
like PIP2, ATP and ATP analogs were found to effectively compete with Wortmannin
for their binding with PI3K, indicating that the binding of Wortmannin to the PI3K
involves the ATP binding pocket. Site directed mutagenesis study by Wymann et al
confirmed that the inhibition of PI3K by Wortmannin is mediated through the
covalent modification of a critical lysine residue (Lys-802) involved in the transfer of
phosphate moiety from ATP to the substrate of PI3K [198].
As discussed earlier, activation of the MEK-ERK pathway requires the
phosphorylation of ERK1/2 on a threonine and a tyrosine residue simultaneously, by
MEK1/2, a dual specificity kinase [199]. MEK 1 and 2 are the two isoforms of MEK
and share approximately 85% sequence similarity [200]. Dudley et al identified and
demonstrated that the synthetic inhibitor, PD98059 [2-(29-amino-39-methoxyphenyl)oxanaphthalen-4-one], can effectively inhibit MEK1/2 thereby preventing the
downstream activation of ERK1/2 and other substrates of the MEK-ERK pathway
[201]. The effective inhibition of the MEK-ERK pathway resulted in the phenotype
reversal of the transformed mouse fibroblast and rat kidney cells [201]. Studies have
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shown that PD98059 is specific for MEK1/2 inhibition and it does not affect the
kinase activity of ERK1/2 or other cellular kinases [201]. Mechanistically, it is a noncompetitive inhibitor of MEK1/2. Binding of PD98059 to MEK inhibits the
phosphoryl transfer from ATP to ERK1/2 by an allosteric mechanism [201]. Such a
non-ATP competitive mechanism was found to enhance the selectivity of this
inhibitor over the ATP-mimetic inhibitors.
Although the PI3K and the MAPK pathways are found to be important in
mediating the downstream effects of SCF dependent c-kit stimulation in various cell
types as discussed earlier, the role of these signaling pathways in regulating the
survival, growth and migration of CPCs is completely unknown. Hence in this study, I
tested if the pathways are activated upon c-kit activation and confirmed the
involvement of these pathways in regulating the survival, growth and migration of
CPCs using Wortmannin and PD98059. The findings of this study indicate that the
PI3K-AKT and MEK-ERK pathways are activated upon c-kit activation and are
essential for the survival or growth and migration of CPCs. A schematic
representation of this chapter is given in Figure 15.
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Figure 15: Schematic illustration of chapter III. Activation of the c-kit receptor by
the ligand SCF leads to the autophosphorylation of critical tyrosine residues and leads
to the activation of the PI3K-AKT and MEK-ERK pathways, confirmed by Western
blot analysis. Inhibition of either or both the PI3K-AKT pathway with Wortmannin
(PI3K inhibitor) or the MEK-ERK pathway with PD98059 (MEK inhibitor) resulted
in the suppression of survival and migration of CPCs after c-kit activation.
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Materials and Methods:
Western blot:
Refer to methods and materials section in chapter II. Primary antibodies used
were anti-c-kit (1in 500; abcam #32363), anti-phospho c-kit (Y703; 1 in 500; Cell
signaling #3073P), anti-AKT (1in 1000; Cell signaling # 4691), anti-phospho AKT
(Thr 308; 1 in 1000; Cell signaling # 13038), anti-ERK1/2 (1in 1000; Cell signaling #
4695P), anti-phospho ERK1/2 (1 in 1000; Cell signaling # 4370P), alpha-tubulin (1 in
3000; Sigma Aldrich # T6074).
PI3K and MEK inhibitors
Wortmannin and PD98059 were purchased from Cell Signaling Technology
and used at 200 nM and 40 μM concentrations, respectively. For the Western blot
analysis, CPCs were serum starved for 24 hours and pre-treated with the inhibitors for
2 hr followed by 20 min of SCF (100 ng/ml) treatment. For the cell viability and
migration assays, cells were pre-treated with the indicated inhibitors for 2 hours prior
to being treated with SCF.

Results:
PI3K and MAPK pathways mediate the pro-growth and chemotactic effects of
SCF/c-kit on CPCs
A schematic representation of our experiments is given in Figure 16. First I
examined if the PI3K-AKT and the MEK-ERK pathways are activated upon c-kit
activation. I treated the CPCs with 100 ng/ml of SCF for varying duration from 5
minutes up to 60 minutes and analyzed the changes in the phosphorylated (i.e.,
activated) AKT and phosphorylated ERK levels by Western blot. I found a significant
increase in the level of phosphorylated AKT within 10 min after SCF treatment, while
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the phosphorylated ERK levels increased as early as 5 min of SCF treatment (Figure
17). These results suggest that both the PI3K-AKT and MEK-ERK pathways are
indeed activated upon c-kit activation in CPCs. In order to understand the contribution
of each of these pathways to the biological effects of SCF/c-kit signaling on CPCs, I
utilized wortmannin, and PD98059 to inhibit the PI3K-AKT and the MEK-ERK
pathways, respectively. As shown in Figure 18, Western blot analysis confirmed that
both inhibitors were effective in down-regulating their corresponding pathways,
indicated by a significant reduction in the levels of activated AKT or activated ERK
in cells co-treated with SCF and the inhibitors. Interestingly, inhibition of the MEKERK pathway also inhibited the PI3K-AKT pathway but not vice versa (Figure 18),
suggesting that MEK-ERK pathway operates upstream of the PI3K-AKT pathway.
As a next step, to test the participation of the PI3K-AKT and MEK-ERK
pathways in the survival or growth and migration of CPCs, I pre-treated them with
these inhibitors (i.e., Wortmannin and PD98059) either individually or in
combination. While treating the cells with inhibitors alone did not affect their cell
numbers, I found that the inhibitor pre-treatment abolished the pro-survival/growth
effect of SCF when the CPCs were cultured under serum starvation (Figure 19A). I
then tested if the pro-migratory effect of SCF is also dependent on PI3K-AKT and/or
MEK-ERK pathways. While SCF alone stimulated cell migration (as shown earlier),
pre-treatment of the cells with either one of the inhibitors or in combination, prior to
the SCF treatment prevented CPCs from migrating towards the SCF gradient (Figure
19B). These results strongly suggest that the PI3K-AKT and the MEK-ERK pathways
are the major pathways that regulate both pro-survival/growth and migratory effects
of c-kit activation in human CPCs.
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A

B

Figure 16: Schematic representation of chapter III experimental approach.
Investigating the mechanism of c-kit activation in mediating the survival, growth and
migration of CPCs. A. Pharmacological inhibition of the PI3K-AKT and MAPK
pathways. CPCs will be treated with inhibitors separately or in combination two hours
before SCF treatment and harvested for cell viability assay at the indicated time point.
B. CPC migration. CPCs will be treated with inhibitors separately or in combination
two hours before adding SCF as a chemoattractant and the number of cells migrated
are analyzed at the indicated time point.
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Figure 17: SCF dependent c-kit stimulation activates the PI3K-AKT and MEKERK1/2 pathways. Human CPCs were either untreated or treated with 100 ng/ml
SCF for increasing duration. Activation of the pathways was determined by
immunoblotting (n=1).
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Figure 18: Inhibition of the PI3K-AKT and MEK-ERK1/2 pathways with the
inhibitors, Wortmannin (PI3K inhibitor) and PD98059 (MEK inhibitor). CPCs
were pre-treated with the inhibitors for 2 hours followed by SCF (100 ng/ml)
mediated c-kit stimulation for 20 minutes. Cells were harvested using laemlli sample
buffer and immunoblotted (n=1).
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C

Figure 19: Pro-survival and chemotactic effect of SCF was abolished by pretreatment with inhibitors. CPCs were serum starved for 24 hours and pre-treated
with 200 nM Wortmannin (PI3K inhibitor) or 40 µM PD98059 (MEK inhibitor) for 2
hours, followed by SCF treatment. A, The pro-survival effect observed under serum
starvation upon SCF dependent c-kit stimulation was abolished with inhibitors pretreatment. Viability was assessed 3 days post-SCF treatment using prestoblue (n=3).
B, 24 hours after plating CPCs on the transwells, they were pre-treated with the
inhibitors for 2 hours followed by replenishing the media in the lower chamber with
or without SCF. CPCs were fixed with 3.7% formaldehyde 24 hours later and stained
with propidium iodide (n=2). C, Representative images of B. All values are
normalized to the untreated control. All experiments were done in quadruplicates.
Values are presented as mean ± SE. *, p<0.05 compared to the DMSO control, #,
p<0.05 compared to SCF.
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Discussion:
Here, I identified for the first time the growth/survival and migration of CPCs
are regulated by c-kit through the activation of the PI3K-AKT and MEK-ERK
pathways. Firstly, I demonstrated the activation of the above two pathways after SCF
mediated c-kit stimulation. Secondly, pharmacological inhibition of these pathways
reduced the viability and chemotaxis of CPCs. This indicates that the PI3K-AKT and
MEK-ERK are the major pathways mediating the survival/growth and migration of
CPCs upon c-kit activation. The findings of this study are well supported by the
reports published by other investigators on the role of PI3K-AKT and MEK-ERK
pathways in several c-kit+ cell types. For example, Haneline et al have shown that
genetic inactivation of the regulatory subunit (p85) of PI3K affects the survival and
proliferation of erythroid and myeloid progenitors [202]. The study reported that
mouse fetal liver deficient in p85 had significantly lesser erythroid and myeloid
progenitors compared to the wild type control. Additionally, upon stimulation with
SCF, the p85 deficient progenitor cells were found to have a significantly lesser rate
of proliferation when compared to the p85 sufficient cells [202], indicating the progrowth/survival effect of this pathway. Moreover, SCF treatment activated the MEKERK pathway that was found to be essential for the proliferation and expansion of
erythroid progenitors [203]. The study demonstrated that the treatment of serum
starved erythroid progenitors with a combination of SCF and erythropoietin (Epo)
induced activation of the MEK-ERK pathway, identified by immunoblotting.
Furthermore, the SCF-Epo combination synergistically increased the number and size
of the erythroid colonies. Inhibition of the MEK-ERK pathway with the MEK
inhibitor PD98059 abolished the pro-growth effect of SCF-Epo combination further
supporting the requirement of this pathway for erythropoiesis. Taken together, the
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above results support the essential role of the PI3K-AKT and MEK-ERK pathways in
regulating the survival/growth in progenitor cell population.
Besides steady state conditions, SCF/c-kit signaling cascade is often activated
and plays a vital role in various tissue injury conditions also [204-206]. For instance,
Sun and colleagues have shown that SCF-c-kit axis is critical for the recruitment of
progenitor cells to the injury site [204]. The authors introduced cryoinjury in a mouse
brain model and observed a significant increase in SCF mRNA and protein levels at
the injury site [204]. Microscopic analysis of the stained sections revealed that the
induction of SCF expression occurred in the cells that are adjacent to the site of injury
and the level of expression reduced with an increase in the distance from the injured
area. The authors also established that SCF can induce the migration and recruitment
of the c-kit+ neuronal stem cells in vitro and in vivo. Taken together, this study
suggests a role for SCF-c-kit axis in mediating the migration of progenitor cells to the
site of injury [204]. Corroborating the above findings, Lutz and co-workers showed
that local intramyocardial injection of SCF improves myocardial homing of
systemically delivered c-kit+ bone marrow-derived stem cells [11]. From the results
of these studies, it is clear that SCF-c-kit signaling has an essential role in the
mobilization and migration of c-kit+ progenitor cells to the wounded area and support
regeneration [91, 207-209]. Interestingly, it was found that following cardiac injury,
the membrane-bound form of SCF is cleaved by MMP-9 and released within bone
marrow, facilitating the mobilization of bone marrow progenitor cells through the
activation of c-kit [91, 95]. Adding more support to this notion, the mobilization of
bone marrow-derived progenitor cells and their recruitment to the injured heart are
severely compromised in the c-kit mutant (KitW/KitW-v) mouse [91], establishing that
activation of c-kit is indeed necessary for homing of the bone marrow-derived
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progenitor cells. In line with the above findings, the data presented here establishes
that the SCF-c-kit axis induces the migration of CPCs by activating the PI3K-AKT
and MEK-ERK pathways.
In addition to its function as a chemotactic signal to recruit c-kit+ bone
marrow progenitor cells, SCF also promotes adhesion of the recruited cells which is
required for its homing to the injury site. For instance, activation of c-kit by SCF
enhances the adhesion of c-kit+ bone marrow cells to fibronectin as well as to the
activated vascular smooth muscle cells following vascular injury [208]. The adhesion
was completely blocked by anti-SCF antibody. These observations suggest that
SCF/c-kit signaling not only provides a chemotactic signal to recruit c-kit+
progenitors to the injury site, but also facilitates their engraftment. Although we have
not examined whether activation of SCF/c-kit signaling can also promote adhesion of
CPCs either to endothelium or injured myocardium, it is tempting to speculate that
SCF/c-kit signaling also positively contributes to adhesion and engraftment of the
transplanted c-kit+ CPCs to the injury areas in the setting of regenerative cardiac cell
therapy.
An interesting finding of the presented study is that the inhibition of the MEKERK pathway also inhibited the PI3K-AKT pathway but not vice versa. This indicates
that at least in CPCs, MEK-ERK functions upstream of PI3K-AKT. Although this is
contrary to what was observed in melanocytes [120] where the inhibition of the PI3KAKT pathway with Wortmannin suppressed the activation of the MEK-ERK pathway,
it supports the dependency of the pathways on each other and substantiates a similar
role played by these two pathways in regulating the cellular responses in various c-kit
positive cell types. While this study compared only the number of cells; treated and
untreated with SCF; that survived at the end of 3 days in serum depletion conditions,

75

it has not tested the contribution of each of these pathways to CPC proliferation and
apoptosis in particular. As this study evidenced the MEK-ERK pathway and the
PI3K-AKT pathway shares a common signaling mechanism, it is very likely that the
inhibition of one or both the pathways will equally affect growth and survival of
CPCs. In order to confirm this, the proliferation and apoptosis of CPCs following ckit activation has to be measured after inhibition of the PI3K-AKT and/or MEK-ERK
pathways. Also as discussed below it is essential to determine the downstream
mediators of these pathways that are activated after c-kit stimulation to understand if
any of them mediates predominantly a pro-survival or anti-apoptotic function.
Although this study identified the involvement of the PI3K-AKT and MEKERK pathway in regulating the migration, survival/growth of CPCs, the downstream
effectors of either of the pathways are not explored. Phosphorylation of AKT and
ERK1/2 has been known to regulate a plethora of downstream mediators. For
example phosphorylation of AKT on its serine and threonine residues regulates
several proteins including pro-apoptotic proteins, Bcl-2-associated death promoter
(BAD) [111] and FOXO [133], proteins that regulate protein synthesis like mTOR
and ribosomal protein S6 kinase [134, 135], proteins that regulate cellular
proliferation, migration, glucose synthesis like GSK3β [146]. Intriguingly, SCF
dependent c-kit activation was found to phosphorylate and inactivate BAD in a PI3KAKT dependent manner, thereby preventing its interaction with the anti-apoptotic
protein Bcl-2 [111]. Free Bcl-2 inhibits cytochrome c release and hence the caspase
cascade thereby inhibiting apoptosis. Also SCF-c-kit axis has been indicated to
promote the proliferation through the upregulation of the ribosomal protein S6 kinase
(pS6K) via the activation of the PI3K-AKT pathway in germ cells [134]. pS6K
induces the expression of the cell cycle regulating protein cyclin D3 and thus
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promotes proliferation of cells. These evidences suggest that the pro-growth/survival
effect mediated by the c-kit activated PI3K-AKT pathway in CPCs may involve one
or more of the effectors mentioned above. Similar to AKT, ERK1/2 phosphorylation
can regulate proteins such as the retinoblastoma protein (Rb) [210], microphthalmia
associated transcription factor (MITF) [37], c-fos, c-jun, etc. For example ERK1/2,
has been shown to phosphorylate and increase the activity of MITF which functions
to regulate the expression of genes that are essential for the proliferation and survival
of cells [211, 212]. Also treating the cells with SCF significantly upregulated the
expression of MITF and hence the proliferation in mast cells supporting the progrowth effect of SCF-c-kit signaling. Altogether the above reports support the
implication that these signaling molecules downstream of AKT and ERK1/2
activation play a role in regulating cell cycle, protein synthesis and apoptosis in CPCs.
Correspondingly, the migration of CPCs mediated by the PI3K-AKT and
MEK-ERK can involve different downstream mediators. Migration studies in COS-7
cells have shown that ERK1/2 phosphorylates and activates the myosin light chain
kinase (MLCK) protein which in turn phosphorylates myosin light chain (MLC)
[213]. Phosphorylation of MLC favors its interaction with actin promoting contraction
of the cytoskeleton and cellular migration. Another study by Jeon et al has shown that
SCF treatment of melanocytes can activate the PI3K-AKT and cause the
phosphorylation of a group of proteins called ERM proteins (Ezrin, Radixin, Moesin)
[194]. Phosphorylation of the ERM proteins is found to be essential in initiating actin
polymerization and cell migration [213]. In light of the above reports, to have a better
understanding of the SCF-c-kit mediated pro-growth/survival and chemotactic effects,
it is essential to investigate the activation and specific role of these downstream
effectors after the stimulation of the PI3K-AKT and MEK-ERK cascade.
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In summary, I demonstrated that the PI3K-AKT and the MEK-ERK pathways
are activated upon SCF dependent c-kit activation and play a role in regulating the
survival/growth and migration of CPCs.

Biological function of these pathways

activated upon c-kit stimulation in CPCs are inter dependent on each other with the
MEK-ERK acting upstream of the PI3K-AKT.

Conclusion and Future Directions:
With the results of this study I demonstrated that c-kit with its ligand SCF is a
key regulator of survival, growth and migration of CPCs. Although the study could
not establish a relationship between c-kit activation and differentiation of CPCs, it
informed that CPCs are partially differentiated by culturing them in the differentiation
media for a longer duration and the dexamethasone dependent differentiation protocol
has to be optimized to implement on CPCs. Mechanistically, my study also
demonstrated the activation of the PI3K-AKT and MEK-ERK pathways downstream
of c-kit activation and its vitality in promoting the survival/growth and migration of
CPCs.
The current data directs a series of future experiments that would aid in a
better understanding on the role of c-kit and CPCs in cardiac regeneration. As
discussed before, these cells provide significant therapeutic benefit besides their poor
survival in vivo indicating a paracrine effect. It will be interesting to elucidate the
release of any pro-growth/survival cytokines by CPCs and if the expression of c-kit
has any role in regulating the secretory function of CPCs. As our laboratory has
identified the expression of SCF by these cells (data not shown), it will be a wise start
to ascertain the relationship between the expression of the c-kit receptor and its ligand
to identify the presence of a feedback loop regulating their function. For this purpose,
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the conditioned media in which the CPCs are grown can be collected and used to
culture cardiomyocytes, smooth muscle cells, endothelial cells and fibroblasts
followed by measuring their cellular properties. The concentrated and conditioned
medium can be subjected to mass spectrometry to identify any released growth factor.
Similarly, the contribution of the niche cells to the survival, growth and migration of
CPCs is not known. To identify this, co-culturing CPCs with cardiomyocytes,
endothelial cells or fibroblasts will be a useful system to recognize the existence and
effect of juxtacrine and/or the paracrine signaling mechanisms exchanged between the
cells on the growth and survival of CPCs.
Constitutively active c-kit mutants have been implicated to cause uncontrolled
proliferation in other c-kit positive cell types like the mast cells and HSCs [188, 214].
However, there is no information on the role of c-kit mutants in CPCs. As the
presented study is the first attempt to characterize the role of c-kit protein in CPCs,
future experiments to explore the role of c-kit mutants in the growth, survival and
migration of CPCs may lead to methods optimizing the survival and/or growth of
CPCs. For example, supposing the CPCs function through the paracrine effect,
overexpressing the mutant c-kit may lead to more proliferation and prolonged survival
of these cells in vivo enhancing the paracrine signaling. Also as mentioned earlier, it
will be informative to analyze the induction of the pro-growth/survival effectors that
are involved downstream of AKT and ERK using quantitative PCR and Western blot
to delineate the specific role of each signaling pathway. In the same line, exploring
the key players of migration downstream of AKT and ERK, like the ERM proteins,
MLCK will help to find mechanisms that synergize with SCF-c-kit axis.
It is meaningful to check for the activation of other molecular pathways like
the Src Family kinase pathway [124] and Wnt- β catenin pathways [173] that are
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implicated to function in other c-kit+ cell types. Such an effort may lead to the finding
of proteins that have more than one role in CPCs or that can be activated by more than
one pathway. Also, discovery of other signaling mechanism in CPCs may guide to the
discovery of growth factors that can synergize with SCF to further promote its cellular
response. In the study presented here, I did not measure the ROS generation directly
after serum starvation or drug induced oxidative stress. Designing experiments to
measure the same in the presence or absence of c-kit activation will provide more
information about the anti-oxidative role of SCF-c-kit signaling. Comparing the
expression of different anti-oxidant enzymes like the catalase, superoxide dismutase,
glutathione peroxidase in CPCs in contrast to other progenitors like the HSCs will
help to identify the relative sensitivity of CPCs to oxidative stress induced by
different ROS. Similarly, the deleterious effects and mechanistic aspects of serum
starvation on CPCs can be tested by checking for the temporal expression of cell cycle
and pro-apoptotic proteins with an increasing duration of serum depletion.
It is critical to validate the in vitro findings of this study in an in vivo model.
For this purpose, genetically engineered CPCs with low and high c-kit expression can
be infused via the intracoronary and/or intramyocardial route in an animal model of
MI. This will be followed by analyzing the growth, survival and migration of the
infused cells at serial time points. Additionally, the regeneration of the injured
myocardium, cardiomyogenesis, angiogenesis, functional improvement and survival
of the animal in different groups can be compared. The results of the in vivo study
will further corroborate c-kit as a target to promote the survival, growth and homing
of CPCs leading to better treatment strategies.
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